Synapse - Early Drug Development Service

Results (461)

A pilot study of lenvatinib plus pembrolizumab in patients with advanced sarcoma

Meeting Abstract

Movva, S.; Avutu, V.; Chi, P.; Dickson, M. A.; Gounder, M. M.; Kelly, C. M.; Keohan, M. L.; Nacev, B. A.; Rosenbaum, E.; Thornton, K. A.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

First-in-human phase 1/2 dose escalation and expansion study evaluating first-in-class eIF4A inhibitor zotatifin in patients with solid tumors

Meeting Abstract

Meric-Bernstam, F.; Sharma, M.; Sommerhalder, D.; Skeel, R. T.; El-Khoueiry, A. B.; Caswell-Jin, J. L.; Patel, P. H.; Rosen, E.
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Clinicopathologic characterization of ERK2 E322K mutation in solid tumors: Implications for treatment and drug development

Meeting Abstract

Liu, D.; Murciano-Goroff, Y. R.; Jee, J.; Arcila, M. E.; Buonocore, D. J.; Gao, J.; Chakravarty, D.; Schram, A. M.; Callahan, M. K.; Friedman, C. F.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Interim analysis of a single-center, single-arm, prospective phase 2 study to evaluate the efficacy and safety of benralizumab for alpelisib rash in metastatic PIK3CA-mutant, hormone receptor-positive breast cancer

Meeting Abstract

Lacouture, M. E.; Pan, A.; Dranitsaris, G.; Harris, U.; Chandarlapaty, S.; Dang, C. T.; Gajria, D.; Gordon, A.; Iyengar, N. M.; Robson, M. E.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Mechanisms of acquired resistance to TRK inhibitors

Meeting Abstract

Harada, G.; Choudhury, N. J.; Schram, A. M.; Rosen, E.; Murciano-Goroff, Y. R.; Falcon, C. J.; Wilhelm, C.; Kaplanis, L. A.; Liu, D.; Chang, J. C.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Dysfunctional CD8+T cells in the tumor microenvironment are associated with response to nivolumab in mismatch repair deficient (dMMR) or hypermutated ovarian (OVCA) or endometrial cancer (EC)

Meeting Abstract

Friedman, C. F.; Zhou, Q.; Iasonos, A.; Holland, A.; Ramirez, L.; Grisham, R. N.; Guo, R.; Lichtman, S. M.; Kyi, C.; Makker, V.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

First-in-human study of PC14586, a small molecule structural corrector of Y220C mutant p53, in patients with advanced solid tumors harboring a TP53 Y220C mutation

Meeting Abstract

Dumbrava, E. E.; Johnson, M. L.; Tolcher, A. W.; Shapiro, G.; Thompson, J. A.; El-Khoueiry, A. B.; Vandross, A. L.; Kummar, S.; Parikh, A. R.; Munster, P. N.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

The bi-steric mTORC1-selective inhibitor RMC-5552 in tumors with activation of mTOR signaling: Preclinical activity in combination with RAS(ON) inhibitors in RAS-addicted tumors, and initial clinical findings from a single agent phase 1/1b study

Meeting Abstract

Burris, H. A. 3rd; Ulahannan, S. V.; Haura, E. B.; Ou, S. H. I.; Capasso, A.; Munster, P. N.; Kitai, H.; Wang, Z.; Hayes, J.; Tao, L.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Preliminary results from FLAGSHP-1: A phase I dose escalation study of ERAS-601, a potent SHP2 inhibitor, in patients with previously treated advanced or metastatic solid tumors

Meeting Abstract

McKean, M.; Barve, M.; Hong, D.; Parikh, A.; Rosen, E.; Yang, J.; Picard, R.; Yi, J.; Brail, L.; Vecchio, D.; more...
European Journal of Cancer (2022)

Fulltext@MSK | Save

Reversion mutations in germline BRCA1/2-mutant tumors reveal a BRCA-mediated phenotype in non-canonical histologies

Journal Article

Murciano-Goroff, Y. R.; Schram, A. M.; Rosen, E. Y.; Won, H.; Gong, Y.; Noronha, A. M.; Janjigian, Y. Y.; Stadler, Z. K.; Chang, J. C.; Yang, S. R.; more...
Nature Communications (2022)

Fulltext@MSK | Save